Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03574779
Title Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer (OPAL)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Tesaro, Inc.

ovary epithelial cancer

ovarian carcinosarcoma

peritoneum cancer

fallopian tube cancer


Bevacizumab + Dostarlimab-gxly + Niraparib

Age Groups: adult | senior
Covered Countries USA | ESP | CAN

No variant requirements are available.